Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Management of non-Rh(D) red blood cell alloantibodies during pregnancy

Melanie S Kennedy, MD
Kenneth J Moise Jr, MD
Section Editors
Arthur J Silvergleid, MD
Louise Wilkins-Haug, MD, PhD
Deputy Editors
Jennifer S Tirnauer, MD
Vanessa A Barss, MD, FACOG


Maternal alloantibodies to red blood cell (RBC) antigens other than Rh(D) are capable of causing clinically significant hemolysis of fetal and newborn RBCs, known as hemolytic disease of the fetus and newborn (HDFN). Once an alloantibody is identified, appropriate testing and estimation of the risk to the fetus are essential to obstetric care.

This topic review discusses the clinical significance of RBC alloantibodies other than anti-Rh(D) during pregnancy. Separate topic reviews discuss Rh(D) alloimmunization, fetal transfusion, and postnatal management of HDFN.

(See "Prevention of Rh(D) alloimmunization in pregnancy".)

(See "Overview of Rhesus D alloimmunization in pregnancy".)

(See "Management of pregnancy complicated by Rhesus (D) alloimmunization".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Sep 8, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Queenan JT, Smith BD, Haber JM, et al. Irregular antibodies in the obstetric patient. Obstet Gynecol 1969; 34:767.
  2. Koelewijn JM, Vrijkotte TG, de Haas M, et al. Risk factors for the presence of non-rhesus D red blood cell antibodies in pregnancy. BJOG 2009; 116:655.
  3. Bowman J, Harman C, Manning F, et al. Intravenous drug abuse causes Rh immunization. Vox Sang 1991; 61:96.
  4. Lappen JR, Stark S, Gibson KS, et al. Intravenous drug use is associated with alloimmunization in pregnancy. Am J Obstet Gynecol 2016; 215:344.e1.
  5. Markham KB, Scrape SR, Prasad M, et al. Hemolytic Disease of the Fetus and Newborn due to Intravenous Drug Use. AJP Rep 2016; 6:e129.
  6. Judd WJ. Guidelines for prenatal and perinatal immuno-hematology, AABB, Maryland 2005.
  7. Schanfield MS. Human immunoglobulin (IgG) subclasses and their biologic properties. In: Blood Bank Immunology, American Association of Blood Banks, Washington DC 1977. p.97.
  8. Laros RK. Erythroblastosis fetalis. In: Blood Disorders in Pregnancy, Laros RK (Ed), Lea & Febiger, 1986. p.106.
  9. Gurevich P, Erina S, Gershon S, Zusman I. The role of the fetal immune system in the pathogenesis of RhD-hemolytic disease of newborns. Hum Antibodies 1997; 8:76.
  10. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 75: Management of alloimmunization during pregnancy. Obstet Gynecol 2006; 108:457.
  11. Koelewijn JM, Vrijkotte TG, van der Schoot CE, et al. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion 2008; 48:941.
  12. Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med 2000; 342:9.
  13. Sabo BH. Evaluation of the neonatal direct antiglobulin test. Notes on low frequency antigens in hemolytic disease of the newborn. In: A Seminar on Perinatal Blood Banking, American Association of Blood Banks, Washington, DC 1978. p.31.
  14. Weinstein L. Irregular antibodies causing hemolytic disease of the newborn: a continuing problem. Clin Obstet Gynecol 1982; 25:321.
  15. Reid ME, Toy PTCY. Erythrocyte blood groups in transfusion. In: Hematology of Infancy and Childhood, 5th ed, Nathan DG, Orkin SH (Eds), WB Saunders, Philadelphia 1998. p.1761.
  16. Moise KJ. Fetal anemia due to non-Rhesus-D red-cell alloimmunization. Semin Fetal Neonatal Med 2008; 13:207.
  17. Caine ME, Mueller-Heubach E. Kell sensitization in pregnancy. Am J Obstet Gynecol 1986; 154:85.
  18. Vaughan JI, Warwick R, Letsky E, et al. Erythropoietic suppression in fetal anemia because of Kell alloimmunization. Am J Obstet Gynecol 1994; 171:247.
  19. Bowman JM, Pollock JM, Manning FA, et al. Maternal Kell blood group alloimmunization. Obstet Gynecol 1992; 79:239.
  20. Weiner CP, Widness JA. Decreased fetal erythropoiesis and hemolysis in Kell hemolytic anemia. Am J Obstet Gynecol 1996; 174:547.
  21. Vaughan JI, Manning M, Warwick RM, et al. Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med 1998; 338:798.
  22. Daniels G, Hadley A, Green CA. Causes of fetal anemia in hemolytic disease due to anti-K. Transfusion 2003; 43:115.
  23. Bowell PJ, Brown SE, Dike AE, Inskip MJ. The significance of anti-c alloimmunization in pregnancy. Br J Obstet Gynaecol 1986; 93:1044.
  24. Wenk RE, Goldstein P, Felix JK. Alloimmunization by hr'(c), hemolytic disease of newborns, and perinatal management. Obstet Gynecol 1986; 67:623.
  25. Kozlowski CL, Lee D, Shwe KH, Love EM. Quantification of anti-c in haemolytic disease of the newborn. Transfus Med 1995; 5:37.
  26. Hackney DN, Knudtson EJ, Rossi KQ, et al. Management of pregnancies complicated by anti-c isoimmunization. Obstet Gynecol 2004; 103:24.
  27. Hughes LH, Rossi KQ, Krugh DW, O'Shaughnessy RW. Management of pregnancies complicated by anti-Fy(a) alloimmunization. Transfusion 2007; 47:1858.
  28. Miller LH, Mason SJ, Clyde DF, McGinniss MH. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med 1976; 295:302.
  29. Bakhtary S, Gikas A, Glader B, Andrews J. Anti-Mur as the most likely cause of mild hemolytic disease of the newborn. Transfusion 2016; 56:1182.
  30. Wu KH, Chang JG, Lin M, et al. Hydrops foetalis caused by anti-Mur in first pregnancy--a case report. Transfus Med 2002; 12:325.
  31. De Young-Owens A, Kennedy M, Rose RL, et al. Anti-M isoimmunization: management and outcome at the Ohio State University from 1969 to 1995. Obstet Gynecol 1997; 90:962.
  32. Matsumoto H, Tamaki Y, Sato S, Shibata K. A case of hemolytic disease of the newborn caused by anti-M: serological study of maternal blood. Acta Obstet Gynaecol Jpn 1981; 33:525.
  33. Furukawa K, Nakajima T, Kogure T, et al. Example of a woman with multiple intrauterine deaths due to anti-M who delivered a live child after plasmapheresis. Exp Clin Immunogenet 1993; 10:161.
  34. Duguid JK, Bromilow IM, Entwistle GD, Wilkinson R. Haemolytic disease of the newborn due to anti-M. Vox Sang 1995; 68:195.
  35. Kanra T, Yüce K, Ozcebe IU. Hydrops fetalis and intrauterine deaths due to anti-M. Acta Obstet Gynecol Scand 1996; 75:415.
  36. Wikman A, Edner A, Gryfelt G, et al. Fetal hemolytic anemia and intrauterine death caused by anti-M immunization. Transfusion 2007; 47:911.
  37. Levine P. Comments on hemolytic disease of newborn due to anti-PP1 P k (anti-Tj a). Transfusion 1977; 17:573.
  38. Desjardins L, Blajchman MA, Chintu C, et al. The spectrum of ABO hemolytic disease of the newborn infant. J Pediatr 1979; 95:447.
  39. McDonnell M, Hannam S, Devane SP. Hydrops fetalis due to ABO incompatibility. Arch Dis Child Fetal Neonatal Ed 1998; 78:F220.
  40. Sherer DM, Abramowicz JS, Ryan RM, et al. Severe fetal hydrops resulting from ABO incompatibility. Obstet Gynecol 1991; 78:897.
  41. Stiller RJ, Herzlinger R, Siegel S, Whetham JC. Fetal ascites associated with ABO incompatibility: case report and review of the literature. Am J Obstet Gynecol 1996; 175:1371.
  42. Gilja BK, Shah VP. Hydrops fetalis due to ABO incompatibility. Clin Pediatr (Phila) 1988; 27:210.
  44. Ziprin JH, Payne E, Hamidi L, et al. ABO incompatibility due to immunoglobulin G anti-B antibodies presenting with severe fetal anaemia. Transfus Med 2005; 15:57.
  45. Drabik-Clary K, Reddy VV, Benjamin WH, Boctor FN. Severe hemolytic disease of the newborn in a group B African-American infant delivered by a group O mother. Ann Clin Lab Sci 2006; 36:205.
  46. Seeho SK, Burton G, Leigh D, et al. The role of preimplantation genetic diagnosis in the management of severe rhesus alloimmunization: first unaffected pregnancy: case report. Hum Reprod 2005; 20:697.
  47. van den Akker ES, Klumper FJ, Brand A, et al. Kell alloimmunization in pregnancy: associated with fetal thrombocytopenia? Vox Sang 2008; 95:66.
  48. American Academy of Pediatrics and the American College of Obstetricians and Gynecologists. Guidelines for Perinatal Care, 7th ed, AAP, ACOG, Elk Grove Village, IL, Washington DC 2012.
  49. Judd WJ. When should tests for unexpected antibodies be done during pregnancy? Transfusion 2011; 51:1366.
  50. Andersen AS, Praetorius L, Jørgensen HL, et al. Prognostic value of screening for irregular antibodies late in pregnancy in rhesus positive women. Acta Obstet Gynecol Scand 2002; 81:407.
  51. Adeniji AA, Fuller I, Dale T, Lindow SW. Should we continue screening rhesus D positive women for the development of atypical antibodies in late pregnancy? J Matern Fetal Neonatal Med 2007; 20:59.
  52. Rothenberg JM, Weirermiller B, Dirig K, et al. Is a third-trimester antibody screen in Rh+ women necessary? Am J Manag Care 1999; 5:1145.
  53. Heddle NM, Klama L, Frassetto R, et al. A retrospective study to determine the risk of red cell alloimmunization and transfusion during pregnancy. Transfusion 1993; 33:217.
  54. McKenna DS, Nagaraja HN, O'Shaughnessy R. Management of pregnancies complicated by anti-Kell isoimmunization. Obstet Gynecol 1999; 93:667.
  55. van Wamelen DJ, Klumper FJ, de Haas M, et al. Obstetric history and antibody titer in estimating severity of Kell alloimmunization in pregnancy. Obstet Gynecol 2007; 109:1093.
  56. Le Roux MG, Pascal O, Andre MT, et al. Non-paternity and genetic counselling. Lancet 1992; 340:607.
  57. Finning K, Martin P, Summers J, Daniels G. Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma. Transfusion 2007; 47:2126.
  58. Li Y, Finning K, Daniels G, et al. Noninvasive genotyping fetal Kell blood group (KEL1) using cell-free fetal DNA in maternal plasma by MALDI-TOF mass spectrometry. Prenat Diagn 2008; 28:203.
  59. Gutensohn K, Müller SP, Thomann K, et al. Diagnostic accuracy of noninvasive polymerase chain reaction testing for the determination of fetal rhesus C, c and E status in early pregnancy. BJOG 2010; 117:722.
  60. van Dongen H, Klumper FJ, Sikkel E, et al. Non-invasive tests to predict fetal anemia in Kell-alloimmunized pregnancies. Ultrasound Obstet Gynecol 2005; 25:341.
  61. Rimon E, Peltz R, Gamzu R, et al. Management of Kell isoimmunization--evaluation of a Doppler-guided approach. Ultrasound Obstet Gynecol 2006; 28:814.
  62. Mari G. Middle cerebral artery peak systolic velocity: is it the standard of care for the diagnosis of fetal anemia? J Ultrasound Med 2005; 24:697.
  63. Oepkes D, Seaward PG, Vandenbussche FP, et al. Doppler ultrasonography versus amniocentesis to predict fetal anemia. N Engl J Med 2006; 355:156.
  64. Moise KJ Jr. The usefulness of middle cerebral artery Doppler assessment in the treatment of the fetus at risk for anemia. Am J Obstet Gynecol 2008; 198:161.e1.
  65. http://www.perinatology.com/calculators/MCA.htm (Accessed on October 14, 2014).
  66. Moise KJ Jr, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol 2012; 120:1132.
  67. Chaplin H Jr, Cohen R, Bloomberg G, et al. Pregnancy and idiopathic autoimmune haemolytic anaemia: a prospective study during 6 months gestation and 3 months post-partum. Br J Haematol 1973; 24:219.
  68. Baumann R, Rubin H. Autoimmune hemolytic anemia during pregnancy with hemolytic disease in the newborn. Blood 1973; 41:293.
  69. Kruskall MS, Leonard S, Klapholz H. Autologous blood donation during pregnancy: analysis of safety and blood use. Obstet Gynecol 1987; 70:938.
  70. Schumacher B, Moise KJ Jr. Fetal transfusion for red blood cell alloimmunization in pregnancy. Obstet Gynecol 1996; 88:137.